SynCore Biotechnology CoROCO:4192 +0.75%67 Quick Ratio is 20.41 as of Dec. 2025, which is 133% above its 10-year median of 8.76. GuruFocus rates ROCO:4192 with a GF Score™ of 67/100 and a GF Value™ of NT$47.79 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, SynCore Biotechnology Co ranks better than 92.77% on this metric.
SynCore Biotechnology Co has a quick ratio of 20.41. It generally indicates good short-term financial strength.
The historical rank and industry rank for SynCore Biotechnology Co's Quick Ratio or its related term are showing as below:
ROCO:4192'
s Quick Ratio Range Over the Past 10 Years
Min: 1.77 Med: 8.76 Max: 20.41
Current: 20.41
During the past 13 years, SynCore Biotechnology Co's highest Quick Ratio was 20.41. The lowest was 1.77. And the median was 8.76.
ROCO:4192's Quick Ratio is ranked better than 92.77% of 1411
companies
in the Biotechnology industry
Industry Median: 3.6
vs ROCO:4192: 20.41
SynCore Biotechnology Co (ROCO:4192) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
SynCore Biotechnology Co Quick Ratio Related Terms
SynCore Biotechnology Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4192 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, SynCore Biotechnology Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SynCore Biotechnology Co Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SynCore Biotechnology Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where SynCore Biotechnology Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
SynCore Biotechnology Co's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SynCore Biotechnology Co (ROCO:4192) has a Quick Ratio of 20.41 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on SynCore Biotechnology Co and its competitors. This is 133% above median its historical median of 8.76. Over the past decade, SynCore Biotechnology Co's Quick Ratio has ranged from 1.77 to 20.41. According to the industry distribution chart, SynCore Biotechnology Co ranks #102 out of 1411 companies in the Biotechnology industry, placing it in the top 7.2%.
Is SynCore Biotechnology Co's Quick Ratio too high?
SynCore Biotechnology Co's current Quick Ratio of 20.41 is 133% above median its 10-year median of 8.76. Over the past 10 years, this metric has ranged from a low of 1.77 to a high of 20.41. The Biotechnology industry median Quick Ratio is 3.60. SynCore Biotechnology Co's value of 20.41 is 466.9% above this industry median. Based on the distribution chart, SynCore Biotechnology Co ranks #102 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SynCore Biotechnology Co has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SynCore Biotechnology Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SynCore Biotechnology Co ranks #102 out of 1411 companies for Quick Ratio. This places SynCore Biotechnology Co in the top 7% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. SynCore Biotechnology Co's value of 20.41 is 466.9% above this benchmark. Historically, SynCore Biotechnology Co's own Quick Ratio has ranged from 1.77 to 20.41 over the past decade. While the company's 10-year median is 8.76 vs. the industry median of 3.60, SynCore Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SynCore Biotechnology Co's current Quick Ratio of 20.41 is 466.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on SynCore Biotechnology Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SynCore Biotechnology Co's current Quick Ratio is 20.41, which is 133% above median its own 10-year median of 8.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynCore Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, SynCore Biotechnology Co (ROCO:4192) is currently considered Possible Value Trap. The stock's GF Value™ is NT$47.79, compared to a current price of NT$20.15 — trading 57.8% below its estimated fair value. The current Quick Ratio is 20.41, which is 133% above median its 10-year median of 8.76 and 466.9% above the Biotechnology industry median of 3.60. SynCore Biotechnology Co's overall GF Score™ is 67/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For SynCore Biotechnology Co (ROCO:4192), the current Quick Ratio is 20.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SynCore Biotechnology Co (ROCO:4192) Overvalued in 2026?
Based on GuruFocus' analysis, SynCore Biotechnology Co stock appears to be undervalued.
The current stock price of NT$20.15 is trading 57.8% below its estimated GF Value™ of NT$47.79.
GuruFocus considers SynCore Biotechnology Co to be Possible Value Trap.
Key valuation signals for ROCO:4192:
Quick Ratio: 20.41 (133% above median its 10-year median of 8.76)
GF Value™: NT$47.79 vs. price of NT$20.15 (57.8% below fair value)
Industry Position: 466.9% above the Biotechnology median (#102 of 1411)
No single metric tells the full story. See the ROCO:4192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SynCore Biotechnology Co Ltd is a biotechnology company. The pipeline products of the company include SB01 and 02, SB03, SB04, SB05, and Others. It is engaged in new drug development and sales, healthy food development and sales, medicine inspection, biotechnology services, and intellectual property. It operates in a single industry, the new drug development. The company generates the majority of its revenue from medical products and healthy food.
67GF Score
Get the complete analysis for ROCO:4192
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4192 has been successfully added to your 
